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Evolution of Vascular Complications in Transfemoral Transcatheter
Aortic Valve Replacement
Brant W. Ullery1, Ruyun Jin1, Eric B. Kirker1, Greg Hayes2, Leland Siwek3, James Brevig4, Robert W. Hodson1, Kateri J. Spinelli1
Background
Vascular complications (VCs) following transfemoral transcatheter aortic valve replacement (TF-
TAVR) have historically been common and associated with significant morbidity and mortality.1,2
We evaluated our large multicenter experience to provide new insight on the incidence, predictors, 
management, and clinical impact of VCs after TAVR.
Results 2
• Ninety-seven major vascular complications occurred in 96 patients (6.1%); majority of major VC 
patients also experienced major or life-threatening bleeding (89 cases, 93%) (Table 1)
• Minor and major VC groups had a higher percentage of female and CLD, with lower rates of 
prior CABG; rates of prior PCI also differed between groups (Table 2)
• Fifty percent of major VCs occurred at the TAVR access site, 53% occurred intra-operatively, 
and 74% required treatment, of which 48% had open surgery as the primary treatment method 
(Table 3)
• Rates of location, timing, and treatment of major VC were similar across the years (Table 3)
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Methods
• Retrospective TVT registry and chart review were performed for 1,573 patients undergoing non-
clinical trial TF-TAVR across 7 centers within our hospital network between January 2012 
through December 2016.
• Vascular and bleeding complications were defined by Valve Academic Research Consortium-2 
definitions.3
• Incidence of 30-day vascular complications, treatment strategy, and outcomes were reported. 
Between-group differences were analyzed by t-test, Fisher exact, Chi-square, ANOVA, or 
Wilcoxon rank sum. 
• Mixed effect model with hospital as a random effect was used to assess predictors of major VC. 
• Kaplan-Meier survival analysis and log-rank test were used to compare 1-year survival for minor, 
major, and no VC groups. Cox proportional hazards model was used to assess predictors of 
mortality at 1-year, for those who survived >30 days. 
Conclusions
Despite a reduction in the incidence of VCs in our multicenter experience, major VCs continue to 
be associated with significant perioperative morbidity and mortality.  These findings reinforce the 
importance of patient and anatomic selection for TF-TAVR, as well as consideration of TAVR with 
alternative access for those with challenging iliofemoral access.
Results 3
• VC patients had higher rates of blood transfusion, longer ICU and post-operative LOS, higher 
rates of significant cardiac event, stroke, wound infection, and 30-day mortality (Table 4)
• 30-day all-cause readmission was similar between VC groups, however 30-day readmission for 
a vascular reason was higher in the major and minor VC groups. (Table 4)
• 1-year survival was lower for patients with major VC. Majority of the death happened within 30-
day of procedure. For patients who survived >30 days, 1-year survival did not differ between 
groups (Figure 1)
• Female gender, Hispanic ethnicity, prior PCI, prior PAD, CLD, TAVR access on right side and 
date of surgery were predictors of major VC. Every 90-day increase in the procedure date 
decreased the odds of having a major VC by 6% (p=0.012). (Table 5).
• For patients who survived >30 days, the predictors of one-year mortality were male gender, BMI 
<18.5, CLD, current home oxygen use, immunocompromised, and STS mortality risk score of 
surgical AVR. After adjusting for the above factors, experiencing a major or minor VC did not 
impact long-term survival (p=0.129 for minor VC vs. no VC; p=0.698 for major VC vs. no VC). 
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Age, years 83.0 (77.0, 87.8) 82.9 (77.0, 87.7) 84.9 (76.8, 88.2) 83.1 (77.9, 89.1) 0.435
Female 713 (45.3%) 603 (43.1%) 46 (59.7%) 64 (66.7%) <0.001
BMI, kg/m2 27.2 (23.8, 32.2) 27.2 (23.8, 32.1) 27.1 (23.8, 30.8) 28.8 (24, 34.9) 0.249
Diabetes 623 (39.6%) 558 (39.9%) 32 (41.6%) 33 (34.4%) 0.533
Chronic lung disease 658 (41.8%) 568 (40.6%) 40 (51.9%) 50 (52.1%) 0.016
Smoker 88 (5.6%) 80 (5.7%) 3 (3.9%) 5 (5.2%) 0.896
Hypertension 1357 (86.3%) 1206 (86.1%) 67 (87%) 84 (87.5%) 0.915
Immunosuppression 248 (15.8%) 214 (15.3%) 13 (16.9%) 21 (21.9%) 0.222
Prior PCI 558 (35.5%) 492 (35.1%) 21 (27.3%) 45 (46.9%) 0.02
Prior CABG 360 (22.9%) 339 (24.2%) 9 (11.7%) 12 (12.5%) 0.002
Prior MI 372 (23.6%) 328 (23.4%) 18 (23.4%) 26 (27.1%) 0.716
Prior shock* 18 (1.1%) 16 (1.1%) 0 (0%) 2 (2.1%) 0.462
Prior cardiac arrest* 6 (0.4%) 6 (0.4%) 0 (0%) 0 (0%) >0.999
Prior aortic valve 172 (10.9%) 153 (10.9%) 12 (15.6%) 7 (7.3%) 0.221
Prior stroke 224 (14.2%) 204 (14.6%) 9 (11.7%) 11 (11.5%) 0.564
Prior PAD 478 (30.4%) 413 (29.5%) 27 (35.1%) 38 (39.6%) 0.076
STS risk of AVR 
mortality, %
6.0 (4.2, 8.6) 6.0 (4.2, 8.5) 6.1 (3.8, 9.4) 7.1 (4.8, 9.4) 0.062
Table 2: Patient Demographics
* Within 24 hours
Data presented as n (%) of patients or median (IQR)
BMI = body mass index, PCI = percutaneous coronary intervention, CABG = coronary artery bypass graft, MI = myocardial infarction, PAD = 
periphery artery disease, INR = international normalized ratio, STS = society of thoracic surgery, AVR = aortic valve replacement.
Figure 2 – Survival: One-year survival for all patients (A) and patients who survived greater 
than 30 days after TAVR (B).
Vascular 
Complications
Bleeding Complications OverallNone Minor Major Life Threatening
None 1396 0 3 1 1399 (89.0%)
Minor 57 20 0 0 77 (4.9%)
Major 6 1 46 43 96 (6.1%)*
Overall 1459 (92.8%) 21 (1.3%) 49 (3.1%) 44 (2.8%) 1573










∆Hgb, pre vs post 2.1 ± 1.3 1.9 ± 1.2 2.3 ± 1.2 4.0 ± 1.5 <.001
RBC Transfusion 165 (10.5%) 96 (6.9%) 16 (20.8%) 53 (55.8%) <.001
RBC units 0.3 (1.3) 0.2 (0.8) 0.7 (2.0) 2.2 (3.1) <.001
ICU hours 31.2 ± 41 28.4 ± 34.6 43.6 ± 61.1 61.3 ± 77.9 <.001
Post-op LOS 3.6 ± 3.8 3.4 ± 3.1 4.5 ± 6.8 6.6 ± 7.2 <.001
Significant cardiac event‡ 26 (1.7%) 2 (0.1%) 1 (1.3%) 23 (24.0%) <.001
Stroke 29 (1.8%) 22 (1.6%) 2 (2.6%) 5 (5.2%) 0.028
Post-op wound infection 3 (0.2%) 1 (0.1%) 0 (0%) 2 (2.1%) 0.017
30-d all-cause readmit 162 (10.3%) 145 (10.4%) 9 (11.7%) 8 (8.3%) 0.753
30-d readmit for vascular 
reason
13 (0.8%) 3 (0.2%) 6 (6.5%) 5 (5.2%) <.001
30-d mortality 42 (2.7%) 25 (1.8%) 2 (2.6%) 15 (15.6%) <.001
Table 4: Outcomes for Patients with Vascular Complications 
Data presented as mean ± SD or n (%) of patients
* During index hospitalization, unless otherwise indicated
‡ Procedure-related significant cardiac event includes coronary compression or obstruction, annular dissection, aortic dissection or cardiac 
perforation
Hgb = hemoglobin, RBC = red blood cell, ICU = intensive care unit, LOS = length of stay, SD = standard deviation
Data presented as n (%) of patients; highest severity of complication was counted 
* One patient had two major VCs
Table 5: Risk Factors for Major Vascular Complications
Major VC: multivariable regression model
Variable OR (95% CI) p-value
Female 3.00 (1.91, 4.72) <.001
Hispanic 3.04 (1.07, 8.69) 0.037
Prior PCI 2.14 (1.38, 3.31) 0.001
Prior PAD 1.65 (1.06, 2.55) 0.025
CLD, moderate or severe 1.61 (1.05, 2.46) 0.027
Laterality of TAVR access sheath, right 2.10 (1.26, 3.50) 0.004
Date of surgery, per 90-day increase 0.94 (0.90, 0.99) 0.012
* For patients who survived >30 days 
‡ Immunosuppressive medication therapy, including systemic steroid therapy, inhaled steroid therapy, or preoperative protocol, 
within 30 days preceding the operative procedure 
OR = odds ratio, CI = confidence interval, PCI = percutaneous coronary artery disease, PAD = periphery artery disease, CLD = 
chronic lung disease, HR = hazard ratio, STS = society of thoracic surgeons
Variable Overall 2012 2013 2014 2015 2016 P-value


















23 (23.7%) 2 (40%) 2 (40%) 3 (20%) 7 (24.1%) 9 (20.9%)
Access, TAVR 
side
49 (50.5%) 3 (60%) 2 (40%) 7 (46.7%) 16 (55.2%) 21 (48.8%)
Non-access 25 (25.8%) 0 (0%) 1 (20%) 5 (33.3%) 6 (20.7%) 13 (30.2%)
Timing 0.936
Intra-op 51 (52.6%) 3 (60%) 2 (40%) 7 (46.7%) 15 (51.7%) 24 (55.8%)
Post-op 46 (47.4%) 2 (40%) 3 (60%) 8 (53.3%) 14 (48.3%) 19 (44.2%)
Received 
treatment
71 (73.2%) 4 (80%) 4 (80%) 11 (73.3%) 19 (65.5%) 33 (76.7%) 0.898
Treatment method 0.861
Open 34 (47.9%) 2 (50%) 2 (50%) 8 (72.7%) 7 (36.8%) 15 (45.5%)
Endo 18 (25.4%) 1 (25%) 1 (25%) 2 (18.2%) 6 (31.6%) 8 (24.2%)
Hybrid 6 (8.5%) 1 (25%) 0 (0%) 0 (0%) 2 (10.5%) 3 (9.1%)
Pericardial drain 9 (12.7%) 0 (0%) 0 (0%) 1 (9.1%) 3 (15.8%) 5 (15.2%)
Thrombin injection 4 (5.6%) 0 (0%) 1 (25%) 0 (0%) 1 (5.3%) 2 (6.1%)
Table 3: Temporal Trends in Major Vascular Complications
Data presented as n (%) of complications.
* One patient had two major VCs
Results 1
